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ABSTRACT
Introduction Prevalence rates of breastfeeding remain
low even though the World Health Organization (WHO) and
the American Academy of Pediatrics recommend exclusive
breast feeding for the first 6 months of life in combination
with appropriate complementary feeding beyond six 6
months of age. There have been several studies that
address the implication of drinking animal milk and/or
infant formula on children’s health and development when
breast feeding is not offered during the first year of life.
Vast improvements have been made in infant formula
design, which may increase its benefits compared with
animal’s milk. The objective of this review is therefore to
synthesise the most recent evidence on the effects of the
consumption of animal milk compared with infant formula
in non-breastfed or mixed breastfed infants aged 6–11
months.
Methods and analysis We will conduct a systematic
review and meta-analysis of studies that assessed the
effect of animal milk compared with formula or mixed-fed
(breastmilk and formula) on infants aged 6–11 months.
The primary outcomes of interest include anaemia,
gastrointestinal blood loss, weight for age, height for
age and weight for height. We will include randomised
and non-randomised studies with a control group. We
will use the Cochrane risk of bias tools to assess the
risk of bias. We will use meta-analysis to pool findings
if the identified studies are conceptually homogenous
and data are available from more than one study. We will
assess the overall quality of evidence using the Grading
of Recommendations Assessment, Development, and
Evaluation approach.
Ethics and dissemination This is a systematic review,
so no patients will be directly involved in the design
or development of this study. The findings from this
systematic review will be disseminated to relevant patient
populations and caregivers and will guide the WHO’s
recommendations on formula consumption versus animal
milk in infants aged 6–11 months.
Trial registration number CRD42020210925.

INTRODUCTION
The World Health Organization (WHO) and
the American Academy of Pediatrics recommend exclusive breastfeeding for the first 6

Strengths and limitations of this study
►► We will search several databases for relevant lit-

erature and will included randomised and non-
randomised studies.
►► We will assess risk-of-bias for each outcome and
use the Grading of Recommendations Assessment,
Development, and Evaluation to assess the overall
quality of evidence.
►► We will conduct subgroup analysis for age group (7
months vs 9 months), country, type of feeding (non-
breastfed versus mixed fed) and type of animal milk.
►► We will conduct meta-analyses if data are available
from more than one study, and if there is clinical and
methodological homogeneity in the included studies.
►► All the included studies may not report the data for
infants 6–11 months of age which will be a limitation of the study.

months of life and continuation of breastfeeding beyond 6 months in combination
with appropriate complementary feedings
for up to 2 years or beyond.1 2 However, prevalence rates of breastfeeding still remain
low in many contexts, with many infants still
being given formula milk or cow’s milk before
or after 6 months of age.3 4 Use of cow’s milk
in infancy has been associated with gastrointestinal blood loss, iron deficiency anaemia
and increased solute load for kidneys.5–8 The
composition of cow’s milk is vastly different
from that of breastmilk and infant formula,
which is manufactured to mimic breastmilk.9
Cow’s milk has a high amount of protein
(3.4 g/100 mL vs 0.7–1.4100 mL in breastmilk),10 and the composition of the protein
is different—50%–80% of breastmilk is
comprised of whey protein versus only 18%
for cow’s milk.9 Ingesting a large amount of
protein in the first year of life has been associated with childhood obesity.6 9 Unmodified goat’s milk also contains high amounts
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of protein and mineral content and low folate content.
Goat’s milk does not appear to have any clear nutritional
advantage over cow’s milk and is not less allergenic.11
There have been several studies that have examined
the implications of drinking animal milk and/or infant
formula on children’s health and development.5 7 12–17
The past two decades have also yielded vast improvements
in the design of infant formulas, which may increase the
benefits of infant formula over animal milk.18 The objective of the proposed review is, therefore, to synthesise the
most recent research on the effects of the consumption
of animal milk compared with infant formula in non-
breastfed or mixed breastfed infants aged 6–11 months
of age.
Objective
For non-breastfed or mixed-fed (breastmilk and formula)
infants 6–11 months of age, is the consumption of animal
milk compared with infant formula, associated with beneficial or adverse outcomes for health and development?

METHODS AND ANALYSIS
Study type
We will include individual and cluster randomised
trials. We will also include quasi-
randomised experimental design studies, defined as those that attempted
to randomly allocate participants to conditions but the
method of randomisation was not truly random.19 For
instance, an example of a quasi-
randomised design is
an experimental study where the randomisation was
attempted but the methods of sequence generation were
inadequate such as randomisation based on date of birth
of participants or date of enrolment in the study etc.
We will also include cohort studies, defined as a study
on a group of participants based on certain criteria (eg,
geography, age and so on) but none of the participants
have the outcome of interest at the time of recruitment
and develop outcomes over time in relation to exposure versus no exposure to a risk factor. A cohort study
could be prospective or retrospective.19 We will exclude
case control studies, case series, case reports and cross-
sectional studies. All analyses will be conducted and
reported separately for randomised and non-randomised
studies.
Population
We will include studies that included apparently healthy
infants 6–11 months of age who were non-
breastfed
or mixed fed (breastmilk and formula) irrespective of
gestational age and birth weight. We will include studies
that started animal milk feeding between 4 months and
11 months of age. If a study includes participants who
began intervention before 4 months of age but includes
participants older than 4 months of age as well, we will
consider that study eligible if more than half (50%) of
the study participants meet the inclusion criteria (ie,
4–11 months of age). We will include studies where
2

participants are diagnosed with HIV or have had HIV
exposure. We will exclude studies if participants are diagnosed with AIDS. We will exclude studies that focused
on breastfed infants only without other types of milk
provided. We will exclude studies with participants
who have chronic diseases such as bronchopulmonary
dysplasia, genetic disorders, aerodigestive problems or
congenital anomalies.
Intervention
We will include studies that assessed the effect of animal
milk in infants 6–11 months of age. The animal milk
could be cow milk, goat milk or camel milk. We will
include studies in which animal milk was the main milk
drink as defined by study authors or more than 50% of
the infant’s milk intake was animal milk. We will include
studies irrespective if the animal milk was boiled or not
boiled, pasteurised or unpasteurised, or if the animal
milk was full-fat, reduced fat or skim milk. We will exclude
studies that used plant-based milk such as rice milk, pea
milk, coconut milk or almond milk.
Comparison
The comparison group in the included studies will be
formula feeding or mixed feeding (ie, breast feeding and
formula feeding). We will include studies irrespective of
the type of formula used; namely, this could include cow’s
milk-
based formula, partially or extensively hydrolysed
formula or plant-
based formulas such as soy formula.
The Federal Food, Drug, and Cosmetic Act defines infant
formula as ‘a food which purports to be or is represented
for special dietary use solely as a food for infants by
reason of its simulation of human milk or its suitability as
a complete or partial substitute for human milk’.20
Outcomes
Primary outcomes
►► Anaemia (dichotomous outcome, as defined by
authors) at 7 months, 9 months, 12 months and the
longest follow-up.
►► Gastrointestinal blood loss (dichotomous outcome
based on stool occult testing) at 7 months, 9 months,
12 months and the longest follow-up.
►► Weight for age (kg or Z scores) at 7 months, 9 months,
12 months and the longest follow-up.
►► Height for age (cm or Z scores) at 7 months, 9 months,
12 months and the longest follow-up.
►► Weight for height Z score at 7 months, 9 months,
12 months and the longest follow-up.
Secondary outcomes
Iron deficiency anaemia (dichotomous outcome)
at 7 months, 9 months, 12 months and the longest
follow-up.
►► Blood iron level (continuous outcome) at 7 months, 9
months, 12 months and the longest follow-up.
►► Blood ferritin level (continuous outcome) at 7 months,
9 months, 12 months and the longest follow-up.
►►
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Haemoglobin concentration in the stool (continuous
outcome) at 7 months, 9 months, 12 months and the
longest follow-up.
►► Haemoglobin concentration in the serum (continuous outcome) at 7 months, 9 months, 12 months and
the longest follow-up.
►► Fatty acid status (continuous outcome) at 7 months, 9
months, 12 months and longest follow-up.
►► Gut health: Diarrhoea (>3 loose stools per day)
(dichotomous outcome) at 7 months, 9 months, 12
months and the longest follow-up.
►► Gut health: Constipation (<3 bowel movements
per week) (dichotomous outcome) at 7 months, 9
months, 12 months and longest follow-up.
►► Pneumonia (as defined by authors) (dichotomous
outcome) at 7 months, 9 months, 12 months and the
longest follow-up.
►► Allergy (IgE-
mediated and non-
IgE-
mediated and
mixed) (dichotomous outcome) at 7 months,
9 months, 12 months and the longest follow-up.
We will include both immunoglobulin E (IgE)-
mediated, non-IgE-mediated and mixed milk allergies.
IgE-mediated allergies can be identified with a skin prick
test or blood test for specific IgE and symptoms typically
arise immediately after ingesting the milk product. Non-
IgE-mediated allergies will not be identified with a skin
prick test or blood test and symptoms typically arise 48
hours after ingestion of milk product.21 Non-IgE-mediated
allergies can be identified using allergen elimination and
standard challenge procedure in which the allergen is
removed from the diet for up to 2 weeks and then reintroduced to determine if symptoms are elicited.22
►► Obesity (dichotomous outcome) at 1 year and longest
follow-up.
Obesity is defined as a body mass index (BMI) at or
above the 95th percentile for children and teens of
the same age and sex.23 It can also be defined as BMI
for age Z scores >3 for children under 5 years of age.
►► Overweight (dichotomous outcome) at 1 year and the
longest follow-up.
Overweight is defined as a BMI at or above the 85th
percentile and below the 95th percentile for children
and teens of the same age and sex.23 It can also be
defined as BMI for age Z scores >2 for children under
5 years of age.
►► Neurodevelopmental
outcomes
(continuous
outcome) at 1 year and the longest follow-up.
The term neurodevelopment is a composite term
that refers to cognitive, neurological and/or sensory
outcomes. This may include intellectual disability as
measured on the Mental Developmental Index of the
Bayley Scales of Infant Development, gross motor delay measured on Gross Motor Function Classification
System and so on.
If a study does not report outcomes at 7 months but
instead reports outcomes at 6 months or 8 months, it will
be included with outcomes at 7 months. Similarly, if a
study does not report outcomes at 9 months but instead
►►
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reports outcomes at 10 months, it will be included with
outcomes at 9 months. If a study does not report outcomes
at 12 months, but instead reports those outcomes at 11,
13 or 14 months, it will be included with outcomes at
12 months.
Literature search
We will conduct systematic electronic searches on multiple
databases, including PubMed, EMBASE, the Cochrane
Central Register for Controlled Trials, Web of Science,
CINHAL, Scopus, WHO Global Index Medicus. There
will be no restrictions applied to the searches based on
outcomes, study design, publication status, publication
date or language. A proposed search strategy for PubMed
is shown in online supplemental appendix 1. We will
search ClinicalTrials.gov to identify ongoing studies. We
will also search the websites of relevant international agencies, such as the WHO (including WHO’s Reproductive
Health Library), UNICEF, Global Alliance for Improved
Nutrition, International Food Policy Research Institute,
International Initiative for Impact Evaluation (3ie),
Nutrition International, World Bank, USAID and affiliates (eg, FANTA, SPRING) and the World Food Program.
The reference sections of previously published reviews
and the latest published studies will also be searched for
potentially eligible studies.
Data extraction and synthesis
Selection of studies
Searches from all the databases will be combined in
bibliographic software (EndNote) and duplicates will be
removed. Two authors (AI and JC or AI and JME) will first
screen the titles to identify potentially eligible studies; any
studies retained at this step will proceed to the second
stage of screening for a full-text review; finally, any studies
deemed eligible during the full-text review will proceed
to the third step of full data extraction. Any conflict will
be resolved by discussion and with the help of the senior
author on the team if needed. We will use coding software (Covidence) to conduct the screening.24 If a study is
only available in abstract form, we will write to authors to
obtain details on methods and results. If a study is available in a language other than English, we will attempt to
have the translation completed using the local resources.
If a study was published in more than one report (multiple
publications), we will count those multiple reports as a
single study and extract information from all the available
reports as needed.
Data extraction
A data extraction sheet will be designed and piloted for
the extraction of information from the selected studies
(online supplemental file 2). Two authors (JME and
JC) will independently extract the data and compare
their findings. Any conflict will be resolved by discussion
and with the help of the senior author on the team if
needed. We will extract the information on type of study
(randomised control trial, quasirandomised experimental
3
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design or cohort study) study site, study year, study population (age, nutritional status, per cent women), methods
for data collection and analysis, intervention (dose, duration, frequency), age of outcome assessment, comparison, outcomes, whether the results were adjusted for
confounders, what confounders were considered (socioeconomic status, maternal employment, maternal age,
maternal level of education, age-
appropriate complementary feeding) and risk of bias (online supplemental
document).
Assessment of risk of bias in included studies
Study risk of bias will be assessed using the Cochrane risk
of bias tool (ROB 2.0)25 for randomised controlled trials
and using the Cochrane risk of bias in non-randomised
studies (ROBINS-I) tool for non-randomised studies of
interventions.26 Two review authors will independently
evaluate and agree on the risk of bias for the individual
studies for an outcome. Any disagreements will be
resolved by discussion and if no agreement can be made,
the senior review author will be consulted. We will assess
the effect of assignment to intervention (the intention-
to-treat effect) by addressing five domains of signalling
questions including: bias arising from the randomisation
process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome and bias in selection of the reported
result. Each domain will get a ranking of low risk of bias,
some concerns of bias or high risk of bias. We will include
quotes from the study for each signalling question as
evidence for our ranking decision. The overall risk of
bias will be determined based on the worst ranking for
individual domains. For example, if only one domain is
ranked ‘some concerns’, then the overall risk of bias will
be ‘some concerns’.

DATA SYNTHESIS
We will develop a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
based on the search strategy and eligibility assessment to
show the flow of included and excluded studies.27 We will
analyse the randomised and non-randomised studies separately. We will report findings from all included studies in
a narrative synthesis and will also conduct meta-analyses
to synthesise evidence across studies quantitatively. Meta-
analyses will be conducted when data are available from
more than one study, and when there is clinical and methodological homogeneity in the included studies. Dichotomous outcomes will be measured using relative risk effect
sizes and will be reported with their corresponding 95%
CIs. Continuous outcomes will be measured using mean
difference effect sizes and will also be reported along
with their 95% CIs. We will use the generic inverse variance weighting method for meta-analysis. We will use the
random effects model for meta-analysis given that there
might be heterogeneity in effects due to variability in the
4

study populations and interventions used. We will use
RevMan28 and Stata29 software for the statistical analysis.
In the case of morbidity outcomes, we will combine
all available data whenever possible if outcomes are
measured in different ways. For example, we will include
all types of diarrhoea (mild, moderate and severe) as a
dichotomous value (yes/no) if participants had greater
than 3 instances of loose stools per day. We will include
occurrence of anaemia, gastrointestinal blood loss based
on stool occult testing, iron deficiency anaemia, pneumonia and allergies (non-IgE, IgE-mediated) throughout
the study as dichotomous values (yes/no). For dichotomous outcomes, we will extract the total number of
participants in each group and the number of participants experiencing an event. We will pool the dichotomous outcomes in a meta-analysis to obtain a summary
estimate in the form of relative risk and report it with
its corresponding 95% CI. We will include haemoglobin
concentration in stool, weight for age, height for age and
weight for height as continuous values. For continuous
outcomes, we will pool the data to obtain a pool mean
difference and report it with its 95% CI. In the event that
data are reported in different units (eg, few studies report
weight in kg and the others report in Z scores), we will use
a standardised mean difference effect size and report it
with its 95% CI.
Unit of analysis issues
Multiple-arm trial
Studies with multiple treatment arms will be included if
eligible. For multiple-arm trials, we will include data in a
way that the only difference between the groups is use of
animal milk.
Cluster trials
Cluster assignment trials will be analysed together with
individual randomised trials. We will use the cluster
adjusted values; if the trial results are not adjusted for
cluster design, we will adjust the result by methods given
in the Cochrane handbook for systematic reviews.19

STUDIES WITH MISSING DATA
We will document attrition during data extraction. If the
authors report the missing data and report the imputations for the missing data, we will use the latter. If data
are missing for some cases, or if reasons for dropout are
not reported, we will contact the trial authors to request
the full data. In the event that a study does not report the
SD for the continuous outcome, we will write to authors
to request the data. If the SD data are not available from
authors, we will use SD from a similar study that has similar
study population. We will prefer to use the final values of
a continuous outcome for a given follow-up. If the final
values are not available but the difference between the
end and the start of the study, we will write to authors to
request the final values. If the final values are not available, we will use the difference or rate of change.
Imdad A, et al. BMJ Open 2021;11:e046370. doi:10.1136/bmjopen-2020-046370
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Assessment of heterogeneity
Assessment of heterogeneity in meta-analysis determines how
different the included studies are from each other. Clinical
heterogeneity refers to differences in patient population or
treatment whereas methodological heterogeneity refers to
differences in how the study was designed. Statistical heterogeneity refers to large differences in the outcome (outside
of chance) that may be due to clinical or methodological
heterogeneity.30 Statistical heterogeneity will be assessed
using Tau,2 χ2 and I2 statistics. We will assess statistical heterogeneity by visual inspection of forest plots, by performing
the χ² test (assessing the p value) and by calculating the Tau2
and I2 statistic. Statistical heterogeneity will be considered
substantial if the p value is less than 0.10, I2 value exceeds
50% and inspection of forest plots show substantial variability
in the effect of the intervention. We will perform subgroup
analysis to determine the reasons for any identified statistical
heterogeneity.
Assessment of reporting bias
Small study and publication bias will be assessed using
funnel plots and regression tests for funnel plot asymmetry when the meta-analysis includes at least ten studies.
Subgroup analysis and investigation of heterogeneity
Age group: 7 months vs 9 months.
If a study does not begin intervention at 7 months but
instead at 6 months or 8 months, it will be included
in the 7 months age subgroup. Similarly, if a study
does not begin intervention at 9 months but instead
at 10 months, it will be included with outcomes at
9 months.
►► Country: Low-
income and middle-
income country
versus high-income country.
►► Type of feeding: non-
breastfeeding versus mixed
feeding.
►► Type of animal milk: Cow, goat, buffalo, camel, sheep.
We will test the subgroups difference by using χ² test.
►►

SENSITIVITY ANALYSIS
Studies with a high overall risk of bias excluded.
Random versus fixed effect meta-analysis model.

►►
►►

Rating of overall quality of evidence
We will assess the overall quality of evidence for the effect
of the intervention on each primary outcome using the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) using the software GradePro.31
The GRADE approach entails identifying and assessing
many different features that affect the certainty of evidence
in the review, including type of study design, statistical
heterogeneity, directness of evidence, within-study risk of
bias, risk of publication bias and precision of effect estimates.32 We will consider evidence from randomised trials
as high quality and downgrade the evidence one level for
serious limitations (table 1).
Imdad A, et al. BMJ Open 2021;11:e046370. doi:10.1136/bmjopen-2020-046370

Table 1 GRADE method for rating the quality of evidence
Study design
Randomised
trial

Quality of
evidence

Lower if

Higher if

High

Risk of bias

Large effect

−1 Serious

+1 Serious

−2 Very serious

+2 Very serious

Inconsistency

 Dose response

−1 Serious

+1 Evidence of a
gradient

−2 Very serious

All plausible
confounding

Indirectness

+1 Would reduce
a demonstrated
effect or

−1 Serious

+1 Would suggest
a spurious effect
when results
show no effect

−2 Very serious

 

Imprecision

 

−1 Serious

 

−2 Very serious

 

Quasi
randomised
trial

Moderate

Publication bias

 

 

Low

−1 Serious

 

 

Very low

−2 Very serious

 

We will rate the overall quality of the body of evidence
as very low (we have very little confidence in the effect estimate), low (we have limited confidence in the effect estimate), moderate (we have moderate confidence in the
effect estimate; the true effect is likely close to the estimate
of the effect) or high (we have high confidence that the true
effect lies close to that of the estimate of the effect). We will
present the results of the GRADE assessment in the form of a
summary of findings tables for the primary outcomes.
AMENDMENTS
We will do the literature searches, screening of titles, selection of studies, data extraction and analysis according to
a priori plan described in this protocol. If we do any additional analysis or change any of the a priori strategies, we
will clearly describe that in the methods section.
Patient and public involvement
No patient or public involvement was considered in
preparation of this protocol.
Consent for publication
Authors give consent for publication of this review.
Availability of data and materials
We will keep all the data available for review by the editors
and peer reviewers and will provide raw data for the
general public on request.
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ETHICS AND DISSEMINATION
This is a systematic review and there will be no direct
contact with the patients. The findings from this systematic review will be disseminated to relevant patient
populations and caregivers as they will be used to guide
recommendations through the WHO on whether the use
of infant formula is better than animal’s milk in infants
aged 6–11 months.
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